Cisplatin
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Antineoplastic Combined Chemotherapy Protocols
Platinum
Platinum. A heavy, soft, whitish metal, resembling tin, atomic number 78, atomic weight 195.09, symbol Pt. (From Dorland, 28th ed) It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as "alutiae".
Drug Resistance, Neoplasm
Drug Administration Schedule
Etoposide
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Ovarian Neoplasms
Combined Modality Therapy
DNA Adducts
Fluorouracil
Paclitaxel
Head and Neck Neoplasms
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
Ifosfamide
Treatment Outcome
Carcinoma, Squamous Cell
Drug Screening Assays, Antitumor
Carcinoma, Non-Small-Cell Lung
Survival Analysis
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Doxorubicin
Taxoids
Infusions, Intravenous
Apoptosis
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Dose-Response Relationship, Drug
Disease-Free Survival
Tumor Cells, Cultured
Testicular Neoplasms
Nausea
Mitomycin
Survival Rate
Camptothecin
Neoplasm Staging
Vindesine
Cell Survival
DNA Damage
Injuries to DNA that introduce deviations from its normal, intact structure and which may, if left unrepaired, result in a MUTATION or a block of DNA REPLICATION. These deviations may be caused by physical or chemical agents and occur by natural or unnatural, introduced circumstances. They include the introduction of illegitimate bases during replication or by deamination or other modification of bases; the loss of a base from the DNA backbone leaving an abasic site; single-strand breaks; double strand breaks; and intrastrand (PYRIMIDINE DIMERS) or interstrand crosslinking. Damage can often be repaired (DNA REPAIR). If the damage is extensive, it can induce APOPTOSIS.
Carcinoma, Small Cell
Bleomycin
Tegafur
Neoplasms, Germ Cell and Embryonal
Antineoplastic Agents, Phytogenic
DNA Repair
The reconstruction of a continuous two-stranded DNA molecule without mismatch from a molecule which contained damaged regions. The major repair mechanisms are excision repair, in which defective regions in one strand are excised and resynthesized using the complementary base pairing information in the intact strand; photoreactivation repair, in which the lethal and mutagenic effects of ultraviolet light are eliminated; and post-replication repair, in which the primary lesions are not repaired, but the gaps in one daughter duplex are filled in by incorporation of portions of the other (undamaged) daughter duplex. Excision repair and post-replication repair are sometimes referred to as "dark repair" because they do not require light.
Germinoma
A malignant neoplasm of the germinal tissue of the GONADS; MEDIASTINUM; or pineal region. Germinomas are uniform in appearance, consisting of large, round cells with vesicular nuclei and clear or finely granular eosinophilic-staining cytoplasm. (Stedman, 265th ed; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1642-3)
Drug Evaluation
Neoplasm Recurrence, Local
Drug Resistance
Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.
Mesothelioma
A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)
Chemotherapy, Adjuvant
Neoplasms
Maximum Tolerated Dose
Epirubicin
Pleural Neoplasms
Ondansetron
Mice, Nude
Amifostine
Carcinoma
Tumor Suppressor Protein p53
Cyclophosphamide
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Radiation-Sensitizing Agents
Induction Chemotherapy
Neoadjuvant Therapy
Osteosarcoma
Remission Induction
Tumour ablation and hepatic decompensation rates in multi-agent chemoembolization of hepatocellular carcinoma. (1/7975)
Thirty-seven cirrhotic patients with 62 hepatocellular carcinoma (HCC) foci--most Child-Pugh class B or C and/or with large, inoperable tumours--underwent 148 sessions of transcatheter arterial chemoembolization (TACE) using lipiodol, doxorubicin and cisplatin. Treatment efficacy was assessed by serial hepatic arteriography in 34/37 (91.9%) patients and abdominal CT scanning in 3/37 (8.1%) patients. Child-Pugh status was determined prior to each treatment session. Varying degrees of control of tumour neovascularity occurred for a median 390 days (range 90 to > 1680 days) in 33/34 (97.1%) patients in whom progress hepatic arteriography was performed. Ablation of tumour neovascularity occurred in 6/6 (100%), 4/12 (33.3%) and 6/16 (37.5%) patients with HCC diameters < 4 cm, 4-7 cm and > 8 cm, respectively (p < 0.02). Significantly more sessions were required for ablation of larger tumours (p < 0.05). Recurrent HCC was detected in 50% of patients after a median 240 days (range 60-1120 days). Deterioration in Child-Pugh status followed a session of TACE on 19/148 (12.8%) occasions but resulted in unscheduled hospitalization on only 4/148 (2.7%) occasions, the highest incidence (8.3%) in Child-Pugh C patients. Actuarial survival was 27/36 (75.0%) at 6 months, 17/34 (50.0%) at 12 months, 14/34 (41.2%) at 18 months, 9/31 (29.0%) at 24 months and 4/27 (14.8%) at 36 months. Multi-agent TACE with lipiodol, doxorubicin and cisplatin provides a useful anti-tumour effect, even in cirrhotic patients with large HCCs. The incidence of clinically significant deterioration in hepatic function due to ischaemia of non-tumorous liver is acceptably low, even in Child-Pugh C patients. (+info)Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). (2/7975)
Twenty-two patients, with locally advanced unresectable and/or metastatic pancreatic carcinoma, received weekly administration of cisplatin 40 mg m(-2), 5-fluorouracil 500 mg m(-2), epidoxorubicin 35 mg m(-2), 6S stereoisomer of leucovorin 250 mg m(-2) and glutathione 1.5 mg m(-2), supported by a daily administration of lenograstim at a dose of 5 microg kg(-1). Nineteen patients were men and three were women. Median age was 63 years (range 47-70). At study entry, pain was present in 15 out of 22 patients (68%) with a mean value of Scott-Huskisson scale of 27.6+/-23.8, whereas a weight loss >10% was present in 15 patients. After eight weekly treatments, three partial responses were achieved for a response rate of 13% (95% CI 0-26%), five patients had stable disease and 14 progressed on therapy. Pain was present in 9 out of 22 patients (40%) with a mean value of Scott-Huskisson scale of 12.3+/-18.4. Eight patients (36%) (three partial response and five stable disease) had a positive weight change. Toxicity was mild: WHO grade III or IV toxicity was recorded in terms of anaemia in 7 out of 188 cycles (3.7%), of neutropenia in 9 out of 188 cycles (4.7%) and of thrombocytopenia in 3 out of 188 cycles (1.5%). Median survival of all patients was 6 months. The outcome of this intensive chemotherapy regimen does not support its use in pancreatic cancer. (+info)Role of dexamethasone dosage in combination with 5-HT3 antagonists for prophylaxis of acute chemotherapy-induced nausea and vomiting. (3/7975)
Dexamethasone (20 mg) or its equivalent in combination with 5-HT3 antagonists appears to be the gold-standard dose for antiemetic prophylaxis. Additional to concerns about the use of corticosteroids with respect to enhanced tumour growth or impaired killing of the tumour cells, there is evidence that high-dosage dexamethasone impairs the control of delayed nausea and emesis, whereas lower doses appear more beneficial. To come closer to the most adequate dose, we started a prospective, single-blind, randomized trial investigating additional dosage of 8 or 20 mg dexamethasone to tropisetron (Navoban), a 5-HT3 receptor antagonist, in cis-platinum-containing chemotherapy. After an interim analysis of 121 courses of chemotherapy in 69 patients, we have been unable to detect major differences between both treatment alternatives. High-dose dexamethasone (20 mg) had no advantage over medium-dose dexamethasone with respect to objective and subjective parameters of acute and delayed nausea and vomiting. In relation to concerns about the use of corticosteroids in non-haematological cancer chemotherapy, we suggest that 8 mg or its equivalent should be used in combination with 5-HT3 antagonists until further research proves otherwise. (+info)MycN sensitizes neuroblastoma cells for drug-induced apoptosis. (4/7975)
Amplification of the MYCN gene is found in a large proportion of neuroblastoma and considered as an adverse prognostic factor. To investigate the effect of ectopic MycN expression on the susceptibility of neuroblastoma cells to cytotoxic drugs we used a human neuroblastoma cell line harboring tetracycline-controlled expression of MycN. Neither conditional expression of MycN alone nor low drug concentrations triggered apoptosis. However, when acting in concert, MycN and cytotoxic drugs efficiently induced cell death. Apoptosis depended on mitochondrial permeability transition and activation of caspases, since the mitochondrion-specific inhibitor bongkrekic acid and the caspase inhibitor zVAD-fmk almost completely abrogated apoptosis. Loss of mitochondrial transmembrane potential and release of cytochrome c from mitochondria preceded activation of caspase-8 and caspase-3 and cleavage of PARP. CD95 expression was upregulated by treatment with cytotoxic drugs, while MycN cooperated with cytotoxic drugs to increase sensitivity to CD95-induced apoptosis and enhancing CD95-L expression. MycN overexpression and cytotoxic drugs also synergized to induce p53 and Bax protein expression, while Bcl-2 and Bcl-X(L) protein levels remained unchanged. Since amplification of MYCN is usually associated with a poor prognosis, these findings suggest that dysfunctions in apoptosis pathways may be a mechanism by which MycN-induced apoptosis of neuroblastoma cells is inhibited. (+info)A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. (5/7975)
Multinuclear platinum compounds have been designed to circumvent the cellular resistance to conventional platinum-based drugs. In an attempt to examine the cellular basis of the preclinical antitumor efficacy of a novel multinuclear platinum compound (BBR 3464) in the treatment of cisplatin-resistant tumors, we have performed a comparative study of cisplatin and BBR 3464 in a human osteosarcoma cell line (U2-OS) and in an in vitro selected cisplatin-resistant subline (U2-OS/Pt). A marked increase of cytotoxic potency of BBR 3464 in comparison with cisplatin in U2-OS cells and a complete lack of cross-resistance in U2-OS/Pt cells were found. A detailed analysis of the cisplatin-resistant phenotype indicated that it was associated with reduced cisplatin accumulation, reduced interstrand cross-link (ICL) formation and DNA platination, microsatellite instability, and reduced expression of the DNA mismatch repair protein PMS2. Despite BBR 3464 charge and molecular size, in U2-OS and U2-OS/Pt cells, BBR 3464 accumulation and DNA-bound platinum were much higher than those observed for cisplatin. In contrast, the frequency of ICLs after exposure to BBR 3464 was very low. The time course of ICL formation after drug removal revealed a low persistence of these types of DNA lesions induced by BBR 3464, in contrast to an increase of DNA lesions induced by cisplatin, suggesting that components of the DNA repair pathway handle the two types of DNA lesions differently. The cellular response of HCT116 mismatch repair-deficient cells was consistent with a lack of influence of mismatch repair status on BBR 3464 cytotoxicity. Because BBR 3464 produces high levels of lesions different from ICLs, likely including intra-strand cross-links and monoadducts, the ability of the triplatinum complex to overcome cisplatin resistance appears to be related to a different mechanism of DNA interaction (formation of different types of drug-induced DNA lesions) as compared with conventional mononuclear complexes rather than the ability to overcome specific cellular alterations. (+info)Testicular cancer: an oncological success story. (6/7975)
Testicular cancer has become a model for a curable neoplasm. Our studies with cisplatin combination chemotherapy allow us to conclude that: (a) short-duration intensive induction therapy with the most active agents in optimal dosage is more important than maintenance therapy; (b) modest dose escalation increases toxicity without improving therapeutic efficacy; (c) it is possible to develop curative salvage therapy for refractory germ cell tumors; and (d) preclinical models predicting synergism, such as vinblastine + bleomycin or cisplatin + etoposide have clinical relevance. Finally, testicular cancer has also become a model for new drug development. Cisplatin was approved by the Food and Drug Administration for testis and ovarian cancer, and etoposide and ifosfamide were approved for refractory germ cell tumors. The success of these studies confirms the importance of the continued search for new investigational drugs in all solid tumors. (+info)Multimodality therapy for locally advanced and limited stage IV breast cancer: the impact of effective non-cross-resistance late-consolidation chemotherapy. (7/7975)
To determine the effectiveness of non-cross-resistant late-consolidation chemotherapy in locally advanced breast cancer (LABC) and stage IV breast cancer, we review our experience with two regimens. Between 1985 and 1991, we enrolled 56 patients with LABC, who were treated with a doxorubicin-based adjuvant regimen, followed by a late-consolidation non-cross-resistant regimen containing methotrexate, 5-fluorouracil, cisplatin, and cyclophosphamide. Between 1985 and 1996, a total of 45 patients with limited stage IV breast cancer underwent surgical excision of all evaluable disease, making them metastatic (stage IV) with no evaluable disease. Surgery was followed by a doxorubicin-containing regimen and then a late-consolidation non-cross-resistant regimen, which was either methotrexate, 5-fluorouracil, cisplatinum, and cyclophosphamide or 5-fluorouracil, mitomycin, etoposide, and cisplatin. Twenty-four patients with limited bone metastases that were unresectable were treated with a doxorubicin-containing regimen, radiation therapy to all sites of disease, and then one of the two late non-cross-resistant regimens. With a median follow-up of 84 months, 78% of patients with LABC are alive, and 68% are free of disease. After a median follow-up of 44 months, 53% of patients with stage IV with no evaluable disease are alive and free of disease. The use of non-cross-resistant late-consolidation chemotherapy is an effective strategy in the treatment of patients with LABC and selected patients with limited stage IV breast cancer. (+info)Modification of non-conservative double-strand break (DSB) rejoining activity after the induction of cisplatin resistance in human tumour cells. (8/7975)
The induction of collateral radioresistance after the development of cisplatin resistance is a well-documented phenomenon; however, the exact processes that are responsible for the cisplatin-induced radioresistance remain to be elucidated. There was no obvious difference in the level of radiation-induced DNA double strand breaks (DSBs), in DSB rejoining rates, or the level of the catalytic subunit of the DNA-dependent protein kinase (DNA-PKcs) in the cisplatin- and radiation-sensitive 2780/WT and cisplatin-resistant 2780/CP cell lines. However, there was a significantly (P < 0.01) lower level of DSB misrejoining activity within nuclear protein extracts derived from the cisplatin- and radiation-sensitive 2780/WT and OAW42/WT tumour cell lines than in similar extracts from their cisplatin- (and radiation-) resistant 2780/CP and OAW42/CP counterparts. All of the DSB misrejoining events involved deletions of between 134 and 444 bp that arose through illegitimate recombination at short repetitive sequences, such as those that arise through non-homologous repair (NHR). These data further support the notion that the radiosensitivity of DSB repair proficient human tumour cell lines may be partly determined by the predisposition of these cell lines to activate non-conservative DSB rejoining pathways. Furthermore, our data suggest that the induction of acquired cisplatin resistance is associated with a two- to threefold decrease in the activity of a non-conservative DSB rejoining mechanism that appears to be a manifestation of NHR. (+info)
O<sup>6</sup>-methylguanine DNA methyltransferase repairs platinum-DNA adducts following cisplatin treatment and predicts...
MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines | Journal of Ovarian Research |...
Raman spectroscopy: A novel experimental approach to evaluating cisplatin induced tissue damage | AVESİS
Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation
Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell...
EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer | BMC Cancer |...
The effects of the antioxidant α-tocopherol succinate on cisplatin-induced ototoxicity in HEI-OC1 auditory cells<...
Sodium butyrate enhances the cytotoxic effect of cisplatin by abrogating the cisplatin imposed cell cycle arrest | Butaren
Dexamethasone for the Prevention of Cisplatin-induced Ototoxicity - Kent Academic Repository
Renal protective effect of a hydration supplemented with magnesium in patients receiving cisplatin for head and neck cancer |...
Chemotherapy with cisplatin and vinorelbine for elderly patients with locally advanced or metastatic non-small-cell lung cancer...
Molecular basis for resistance to the anticancer drug cisplatin in DictyosteliumThe GenBank accession numbers for the sequences...
The mTORC2 Component Rictor Contributes to Cisplatin Resistance in Human Ovarian Cancer Cells<...
Photoaffinity Labeling Reveals Nuclear Proteins That Uniquely Recognize Cisplatin−DNA Interstrand Cross-Links
erbB-2 Signaling Enhances Cisplatin-induced Cytotoxicity in Human Breast Carcinoma Cells: Association between an Oncogenic...
Induktion und Reparatur von DNA-Doppelstrangbrüchen nach kombinierter Einwirkung von Cisplatin und Bestrahlung auf eukaryote...
ADP sensitizes ZL55 cells to the activity of cisplatin
Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer - Full Text...
Epidermal Growth Factor Protects Squamous Cell Carcinoma against Cisplatin-Induced Cytotoxicity through Increased Interleukin...
Transscleral permeability and intraocular concentrations of cisplatin from a collagen matrix. - Semantic Scholar
The mechanisms underlying the proapoptotic effect of the chemotherapeutic agent, cisplatin, | Pharmacokinetic interaction of...
Gemcitabine and cisplatin treatment of advanced-stage non-small-cell lung cancer in patients given cisplatin on day 8
Bcl-2 confers survival in cisplatin treated cervical cancer cells: circumventing cisplatin dose-dependent toxicity and...
DBL CISPLATIN INJECTION (cisplatin injection) | Pfizer Medical Information - Australia
Aging | Cancer-associated fibroblasts secreted miR-103a-3p suppresses apoptosis and promotes cisplatin resistance in non-small...
RePub, Erasmus University Repository:
A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced...
Peripheral neuroglial death induced by cisplatin administration in newborn rats<...
Triplet chemotherapy with paclitaxel, gemcitabine, and cisplatin as second-line therapy for advanced urothelial carcinoma
Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of...
High-Dose Cisplatin Therapy for Cancer for the Ovary: Neurotoxicity | Annals of Internal Medicine | American College of...
Cisplatin Chemoradiation Course in Locally Advanced Head and Neck Cancer - The ASCO Post
Aging | MiR-124 sensitizes cisplatin-induced cytotoxicity against CD133|sup|+|/sup| hepatocellular carcinoma cells by targeting...
Schedule-dependent interactions between pemetrexed and cisplatin in human carcinoma cell lines in vitro
Cancers | Free Full-Text | Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side...
Use of organotypic cultures of Cortis organ to study the protective effects of antioxidant molecules on cisplatin-induced...
Effect of miR-29 on cisplatin sensitivity of ovarian cancer cells<...
Evaluation of mitochondria in mouse oocytes following cisplatin exposure - DOAJ
The effects of cisplatin on developing nociceptive pathways - Nottingham ePrints
Effect of N-acetylcysteine route of administration on chemoprotection against cisplatin-induced toxicity in rat models<...
Plus it
Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab...
Differences in gene expression profiles and carcinogenesis pathways involved in cisplatin resistance of four types of cancer
JCI -
Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of...
JCI -
Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of...
IL-10 from dendritic cells but not from T regulatory cells protects against cisplatin-induced nephrotoxicity<...
Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer | Oncogene
Erythropoietin enhances recovery after cisplatin‐induced acute renal failure in the rat : Nephrology Dialysis Transplantation -...
Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma<...
High temperature requirement A3 (HtrA3) promotes etoposide- and cisplatin-induced cytotoxicity in lung cancer cell lines<...
Expression of p53 in cisplatin-resistant ovarian cancer cell lines: Modulation with the novel platinum analogue (1R, 2R-...
Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer<...
Cisplatin resistant spheroids model clinically relevant survival mechanisms in ovarian tumors<...
SENSITIZATION OF HUMAN OSTEOSARCOMA CELL LINE 143B WITH CALCITRIOL FOR CISPLATIN THERAPY
NSC109268 potentiates cisplatin-induced cell death in a p53-independent manner<...
Addition of Induction Gemcitabine/Cisplatin to Chemoradiotherapy in Nasopharyngeal Carcinoma - The ASCO Post
Preventive effect of prostaglandin E1 on cisplatin-induced nephrotoxicity<...
Evaluation of the effects of taurine on cisplatin-induced kidney injury and oxidative stress in male rats - Physiology and...
Salicylate protects hearing and kidney function from cisplatin toxicity without compromising its oncolytic action<...
Protective effects of apocynin on cisplatin-induced ototoxicity in an auditory cell line and in zebrafish<...
Prophylactic effect of diacerein against cisplatin-induced nephrotoxicity in rats<...
Glutathione transferase omega 1-1 (GSTO1-1) plays an anti-apoptotic role in cell resistance to cisplatin toxicity | IRIS...
Cisplatin-induced apoptosis in p53-deficient renal cells via the intrinsic mitochondrial pathway<...
Acetyl-11-keto-β-boswellic acid enhances the cisplatin sensitivity of non-small cell lung cancer cells through cell cycle...
Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro |...
A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with...
Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer : Medical resource use, costs, and...
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for...
Cis-diamminedichloroplatinum | definition of Cis-diamminedichloroplatinum by Medical dictionary
Foxo3a expression and acetylation regulate cancer cell growth and sensitivity to cisplatin<...
Cisplatin induces protective autophagy through activation of BECN1 in | DDDT
Combination Treatment with BEC and Cisplatin Synergistically Augments Anticancer Activity and Results in Increased Absolute...
The influence of tumour microenvironmental factors on the efficacy of cisplatin and novel platinum(IV) complexes. - The...
Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing...
Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two...
SPIRE - combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study...
Retrospective study of irinotecan/cisplatin followed by etoposide/cisplatin or the reverse sequence in extensive-stage small...
Induction Chemotherapy with Cisplatin and 5-Fluorouracil in Advanced Head and Neck Cancers: A Short Term Response Evaluation ...
The roles of copper transporters in cisplatin resistance<...
Determination of cisplatin, transplatin and amminetri-chloroplatinate by high performance liquid chromatography in one run...
Effects of genistein on anti-tumor activity of cisplatin in human cervical cancer cell lines
Plus it
No data available that match "cisplatin"
588-Head and neck SCC local advanced induction TPF (DOCEtaxel ciSplatin fluorouracil) (part 1) | eviQ
Reduce cisplatin by 25%. 30 to less than 50. Reduce fluorouracil by 25% and cisplatin by 50% or consider substituting ... Cisplatin. Commence prehydration for cisplatin:. *administer 10 mmol magnesium sulphate (MgSO4) in 1000 mL sodium chloride 0.9 ... Arm 1 (TPF): docetaxel 75mg/m2 and cisplatin 100 mg/m2 on day 1 followed by fluorouracil 1000 mg/m2/day from day 1 to day 4 Arm ... ciSplatin. 100 mg/m2 (IV infusion) in 1000 mL sodium chloride 0.9% over 60 minutes. ...
Cisplatin | SpringerLink
Cisplatin | SpringerLink
Yang Q, et al. Concurrent chemoradiotherapy versus intensitymodulated radiotherapy alone for elderly nasopharyngeal carcinoma patients with pre-treatment Epstein-Barr virus DNA: A cohort study in an endemic area with long-term follow-up. Journal of Cancer 9: 3023-3031, No. 17, 30 Jul 2018. Available from: URL: http://doi.org/10.7150/jca.26145 - ChinaCrossRefPubMedPubMedCentralGoogle Scholar ...
Cisplatin Accord - Drugs.com
A list of US medications equivalent to Cisplatin Accord is available on the Drugs.com website. ... Cisplatin Accord is a medicine available in a number of countries worldwide. ... Cisplatin Accord may be available in the countries listed below.. Ingredient matches for Cisplatin Accord. Cisplatin. Cisplatin ...
Cisplatin - National Cancer Institute
This page contains brief information about cisplatin and a collection of links to more information about the use of this drug, ... Cisplatin is approved to be used alone or with other drugs to treat:. *Bladder cancer that cannot be treated with surgery or ... More About Cisplatin. Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug. ... MedlinePlus Information on Cisplatin - A lay language summary of important information about this drug that may include the ...
CISPLATIN (injection, solution) | Healthgrades.com
Cisplatin - Wikipedia
"Cisplatin". Drug Information Portal. U.S. National Library of Medicine. IARC Monograph: "Cisplatin" Medicine portal. ... It is suggested that an antibody reacting with a cisplatin-red-cell membrane is responsible for hemolysis. Cisplatin interferes ... cisplatin is used in Auger therapy.[medical citation needed] Cisplatin has a number of side effects that can limit its use: ... adducts formed by cisplatin in abundance. Cisplatin is the square planar coordination complex cis-[Pt(NH3)2Cl2]. The prefix cis ...
Cisplatin: uses, treatment and side effects
Cisplatin is a platinum-based chemotherapy medicine used to treat cancer. Heres how it works, who should avoid it and the ... How cisplatin treatment given?. Cisplatin infusion is given via a drip into a vein (intravenous infusion). The infusion can ... Cisplatin is often used in combination with other chemotherapy medicines.. Heres everything you need to know about cisplatin, ... Cisplatin: uses and side effects. Cisplatin is a platinum-based chemotherapy medicine used to treat cancer. ...
Cisplatin (Intravenous Route) Precautions - Mayo Clinic
If cisplatin accidentally seeps out of the vein into which it is injected, it may damage some tissues and cause scarring. Tell ... Cisplatin may lower your bodys resistance and there is a chance you might get the infection the immunization is meant to ... Cisplatin can temporarily lower the number of white blood cells in your blood, increasing the chance of getting an infection. ... While you are being treated with cisplatin, and after you stop treatment with it, do not have any immunizations (vaccinations) ...
Cisplatin - Drug Information - Chemocare
Cisplatin (Platinol, CDDP) chemotherapy side effects, how its given, how it works, precautions and self care tips for treatent ... If cisplatin escapes from the vein it can cause tissue damage. The nurse or doctor who gives cisplatin must be carefully ... Cisplatin side effects will improve after therapy is complete.. *Cisplatin side effects may be quite manageable. There are many ... How Cisplatin Is Given:. *Cisplatin is administered through a vein (intravenously or IV) as an infusion. ...
DailyMed - CISPLATIN injection, solution
cisplatin (UNII: Q20Q21Q62J) (cisplatin - UNII:Q20Q21Q62J) cisplatin. 1 mg in 1 mL. ... The active ingredient, cisplatin USP, is a yellow to orange crystalline powder. Cisplatin is a heavy metal complex containing a ... Cisplatin is mutagenic in bacteria and produces chromosome aberrations in animal cells in tissue culture. In mice cisplatin is ... Cisplatin Injection is a clear, colorless, sterile aqueous solution. Each 100 mL amber vial of Cisplatin Injection contains: 1 ...
Cisplatin - Wikipedia
Cisplatin: The Invention of an Anticancer Drug by Andri Smith. *Anti-cancer Agents: A treatment of Cisplatin and their ... Cisplatin resistanceEdit. Cisplatin combination chemotherapy is the cornerstone of treatment of many cancers. Initial platinum ... "Cisplatin". International Drug Price Indicator Guide. Retrieved 8 December 2016.. *^ British national formulary: BNF 69 (69 ed ... Cisplatin". Annals of Internal Medicine. 100 (5): 704-13. doi:10.7326/0003-4819-100-5-704. PMID 6370067.. ...
cisplatin | Cigna
Cisplatin is used together with other medications to treat bladder cancer, testicular cancer, or ovarian cancer. Cisplatin may ... Cisplatin is a cancer medication that interferes with the growth of cancer cells and slows their growth and spread in the body ... How is cisplatin given?. Cisplatin is injected into a vein through an IV. You will receive this injection in a clinic or ... What other drugs will affect cisplatin?. Cisplatin can harm your kidneys. This effect is increased when you also use certain ...
Cellular Responses to Cisplatin-Induced DNA Damage
Interaction of Cisplatin with Glutathione. When cancer cells are exposed to cisplatin, the platinum atom in cisplatin is ... How cells respond to cisplatin-induced DNA damage plays a critical role in deciding cisplatin sensitivity. Cisplatin-induced ... Efflux of cisplatin from the cells by the ATP-dependent transporters, ATP7A and ATP7B. [. 3. ]. Cisplatin binds to cellular ... Cisplatin increased p53 and decreased XIAP in cisplatin-sensitive ovarian cancer 2008 cells but not in cisplatin-resistant ...
Cisplatin and fluorouracil (5FU) - Macmillan Cancer Support
Cisplatin and fluorouracil (5FU) chemotherapy treats cancers of the gullet (oesophagus), head and neck, and anus. It may also ... How cisplatin and 5FU is given. You will have cisplatin and 5FU in the chemotherapy day unit or during a short stay in hospital ... What is cisplatin and 5FU?. Cisplatin and fluorouracil (5FU) is a combination chemotherapy treatment used to treat cancers of ... Your course of cisplatin and 5FU. You usually have a course of several cycles of treatment over a few months. Cisplatin and 5FU ...
Cisplatin - Information and support - Macmillan Cancer Support
What is cisplatin?. Cisplatin is a chemotherapy drug used to treat testicular, ovarian, bladder, head and neck, and non-small ... How cisplatin is given. You usually have cisplatin in the chemotherapy day unit or during a stay in hospital. A chemotherapy ... Each cycle of cisplatin usually takes 21 days (three weeks). You usually have the cisplatin on the first day of the cycle. But ... Possible side effects of cisplatin. We explain the most common side effects of cisplatin here. But we dont include all the ...
Bacteriotherapy Heals Cisplatin Damage | Moffitt
... with fecal pellets before chemotherapy reduces intestinal damage and systemic inflammation in response to cisplatin. ... Bacteriotherapy Heals Cisplatin Damage * NHLBI selects Moffitt Cancer Center as one of the Cell Therapies Processing Facilities ... Bacteriotherapy Heals Cisplatin Damage * S100A9-Induced Overexpression of Pd-1/Pd-L1 Contributes to Ineffective Hematopoiesis ... The new study indicates that cisplatin induces significant changes in the repertoire of intestinal commensal bacteria, which ...
New Guideline Recommends Sodium Thiosulfate to Prevent Cisplatin-Induced Ototoxicity
Sodium thiosulfate can be used to prevent cisplatin-induced ototoxicity in children and adolescents with cancer, according to a ... Cisplatin-induced ototoxicity is permanent and progressive. A clinical-practice guideline is available for ototoxicity ... NEW YORK (Reuters Health) - Sodium thiosulfate can be used to prevent cisplatin-induced ototoxicity in children and adolescents ... Cite this: New Guideline Recommends Sodium Thiosulfate to Prevent Cisplatin-Induced Ototoxicity - Medscape - Jan 16, 2020. ...
Evaluation of mitochondria in mouse oocytes following cisplatin exposure - DOAJ
Abstract Background Cisplatin is a platinum-based chemotherapeutic that damages genomic DNA leading to cell death. It also ... Cisplatin is known to damage the DNA of oocytes, but the possibility that cisplatin also compromises oocyte survival and ... To begin to address this question, neonatal mice were treated with saline or cisplatin (2 mg/kg or 4 mg/kg) and the short and ... Abstract Background Cisplatin is a platinum-based chemotherapeutic that damages genomic DNA leading to cell death. It also ...
Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer | Oncogene
Phenotypic responses to cisplatin were quantified with respect to cell number, proliferation rate and apoptosis, and then ... Overall, our results suggest that, in epithelial-like ovarian cancer cells, NF-κB activation by cisplatin may lead to defective ... Ovarian cancer cell lines with an epithelial status exhibited higher resistance to cisplatin treatment in the MTS assay than ... The current study explored the connection between cellular responses to cisplatin and EMT in ovarian cancer. Expression ...
Cisplatin resistance and oncogenes--a review
Several mechanisms have been implicated in cisplatin resistance, including reduced drug uptake, increased cellular … ... Cisplatin is among the most widely used broadly active cytotoxic anticancer drugs; however, its clinical efficacy is often ... Cisplatin resistance and oncogenes--a review Anticancer Drugs. 2000 Apr;11(4):225-36. doi: 10.1097/00001813-200004000-00001. ... Cisplatin is among the most widely used broadly active cytotoxic anticancer drugs; however, its clinical efficacy is often ...
Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours. - PubMed - NCBI
Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.. Meyer T1, Qian W2, Caplin ... with or without cisplatin (Cis) 70 mg/m(2) intravenously on day 1. The primary outcome measure was objective response. ... to investigate whether capecitabine combined with streptozocin was an acceptable regimen with or without adding cisplatin. ...
Concurrent Daily Cisplatin and Hi... preview & related info | Mendeley
Concurrent Daily Cisplatin and High-Dose Radiation Therapy in Patients With Stage III Non-Small Cell Lung Cancer. *Dieleman E ... Concurrent Daily Cisplatin and High-Dose Radiation Therapy in Patients With Stage III Non-Small Cell Lung Cancer. International ... CCRT consisted of daily low-dose cisplatin (6 mg/m 2 ) combined with 24 fractions of 2.75 Gy to a total dose of 66 Gy. Results ... CCRT with daily low-dose cisplatin for locally advanced stage III NSCLC resulted in promising overall survival (3-year survival ...
Preclinical studies identifying carboplatin as a viable cisplatin alternative
The claims of eight cisplatin analogues as viable alternatives to the parent drug are discussed in terms of their toxicities, ... Preclinical studies identifying carboplatin as a viable cisplatin alternative Cancer Treat Rev. 1985 Sep;12 Suppl A:21-33. doi ... The claims of eight cisplatin analogues as viable alternatives to the parent drug are discussed in terms of their toxicities, ...
Cisplatin (Intravenous Route) Description and Brand Names - Mayo Clinic
Infection-Cisplatin decreases your bodys ability to fight infection * Kidney disease-Effects of cisplatin may be increased ... Information about this cisplatin-intravenous-route. Pregnancy Category. Explanation. All Trimesters. D. Studies in pregnant ... If cisplatin accidentally seeps out of the vein into which it is injected, it may damage some tissues and cause scarring. Tell ... Cisplatin belongs to the group of medicines known as alkylating agents. It is used to treat cancer of the bladder, ovaries, and ...
Cisplatin (Cisplatin Injection): Uses, Dosage, Side Effects, Interactions, Warning
Cisplatin Injection) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related ... Cisplatin Injection (cisplatin injection (cisplatin (cisplatin injection) injection) ) is supplied as follows:. NDC 55390-099- ... Cisplatin (cisplatin injection) can cause fetal harm when administered to a pregnant woman. Cisplatin (cisplatin injection) is ... Cisplatin injection (cisplatin injection (cisplatin (cisplatin injection) injection) ) is indicated as therapy to be employed ...
CiNii Articles -
Clinicopathological report of cisplatin encephalopathy
頭痛,発熱,痙攣,意識障害で発症し,経過中に一過性の皮質盲を呈したシスプラチン脳症の1剖検例 [in Japanese] Clinicopathological report of cisplatin encephalopathy [in ... Encephalopathy following cisplatin, bleomycin and vinblastine therapy for non-seminomatous germ cell tumor of testis HITCHINS ... Ototoxicity in patients receiving cisplatin : Importance of dose and method of drug administration REDDEL RR. ... Seizures and cortical dysfunction
TIP, Paclitaxel, Ifosfamide, Cisplatin Articles
Chemotherapeutic Synergy: Cisplatin | GreenMedInfo | Keyword
The combined use of 1,25(OH)2D3 and cisplatin may be used as a strategy to overcome resistance to cisplatin and dose ... Magnesium improves cisplatin-mediated tumor killing while protecting against cisplatin-induced nephrotoxicity.Jul 31, 2017. ... Curcumin potentiates Cisplatin-induced proliferation inhibitory effect and apoptosis in A549 and Cisplatin resistant lung ... Additional Keywords : Chemotherapeutic Synergy: Cisplatin, Chemotherapy-Induced Toxicity: Cisplatin, Inflammation, Lipid ...
cisplatin intravenous Reviews and User Ratings: Effectiveness, Ease of Use, and Satisfaction
Find user ratings and reviews for cisplatin intravenous on WebMD including side effects and drug interactions, medication ... 6 Cisplatin treatments @ 1/wk. 7 wks radiation to head and neck. Now cancer free ... BUT ... severe fatigue and chemo brain 6 ... 6 Cisplatin treatments @ 1/wk. 7 wks radiation to head and neck. Now cancer free ... BUT ... severe fatigue and chemo brain 6 ... Read user comments about the side effects, benefits, and effectiveness of cisplatin intravenous. ...
ChemotherapyReduced cisplatin-inducedAcquired resistanceEffects of cisplatinAdministration of cisplatinNephrotoxicityToxicityApoptosisInjectionCarboplatinDrug cisplatinPlus cisplatinReceive cisplatinCDDPOvarianTesticular cancerSensitivityIntravenouslyOtotoxicityRespond to cisplatinActivity of cisplatinEffectiveness of cisplatinIntravenousAbstractTherapeuticDosesFluorouracilCytotoxicBladder cancerVinblastinePrevention of cisplatin-inducedImproved by cisplatin treatmentMinutes of cisplatin administrationControlling cisplatin induced nauseaClinicalNauseaMechanismEfficacyProteinInfusionCancer cells to cisplatinKidneyTherapyCervical cancerGeneration of reactive oxygenSodiumTumorsPlatinol-AQDose of cisplatinCycles of cisplatinKnown that cisplatinResponse to cisplatinResponses to cisplatinDocetaxel and cisplatinGemcitabine and CisplatinPlatinum-based chemotherapeuticChemotherapeuticTumor growth
Chemotherapy40
- Cisplatin injection must be given in a hospital or medical facility under the supervision of a doctor who is experienced in giving chemotherapy medications for cancer. (medlineplus.gov)
- You will be given docetaxel and cisplatin in the chemotherapy day unit or during a stay in hospital. (macmillan.org.uk)
- Cisplatin is a platinum-based chemotherapy medicine used to treat cancer. (netdoctor.co.uk)
- Cisplatin is a platinum-based chemotherapy medicine used to treat a variety of cancers, including bladder cancer, cervical cancer , head and neck cancer, lung cancer, testicular cancer and cancer of the ovaries. (netdoctor.co.uk)
- Cisplatin is often used in combination with other chemotherapy medicines. (netdoctor.co.uk)
- Etoposide and cisplatin, known as EP (or sometimes PE), is a combination chemotherapy treatment used to treat different cancers. (macmillan.org.uk)
- Cisplatin is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. (chemocare.com)
- Cisplatin is a chemotherapy medication used to treat a number of cancers . (wikipedia.org)
- cisplatin is one of the most emetogenic chemotherapy agents, but this symptom is managed with prophylactic antiemetics ( ondansetron , granisetron , etc.) in combination with corticosteroids . (wikipedia.org)
- Bacteriotherapy with fecal pellets before chemotherapy reduces intestinal damage and systemic inflammation in response to cisplatin, according to new research from Moffitt Cancer Center that was published online by The Journal of Leukocyte Biology . (moffitt.org)
- Cisplatin and Teysuno (pronounced tay-soon-oh) is a combination of chemotherapy drugs. (cancerresearchuk.org)
- Cisplatin is a chemotherapy drug that works by damaging the DNA in cancer cells and stopping them from multiplying. (cancerresearchuk.org)
- Cisplatin (cisplatin injection) , as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received cisplatin (cisplatin injection) therapy. (rxlist.com)
- As compared with the standard regimen of cisplatin and fluorouracil, induction chemotherapy with the addition of docetaxel significantly improved progression-free and overall survival in patients with unresectable squamous-cell carcinoma of the head and neck. (nih.gov)
- He said that patients who are candidates for chemotherapy should now receive topotecan/cisplatin, rather than single-agent cisplatin. (cancernetwork.com)
- nearly 80% received radiation therapy, and almost 60% had received prior cisplatin-based chemotherapy. (cancernetwork.com)
- This research study is evaluating how well triple negative breast cancer responds to preoperative treatment with Cisplatin or Paclitaxel chemotherapy, and if use of a research test Homologous Recombination Deficiency (HRD) assay can predict response to preoperative treatment. (clinicaltrials.gov)
- Paclitaxel plus ifosfamide and cisplatin is considered as a standard salvage chemotherapy in relapsed good prognosis GCTs, however, up to 40% of favourable prognosis patients failed to achieve durable response to this combination, and therefore new treatment strategies are warranted. (clinicaltrials.gov)
- The resurgence of platinum-based chemotherapy in the last few years has renewed interest in the field, including clinical studies of cisplatin in combination with resistance modulators. (pnas.org)
- or induction chemotherapy with cisplatin and 5FU followed by radiation. (medpagetoday.com)
- Otonomy also intends to initiate clinical development for OTO-104 in a second indication, the prevention of hearing loss associated with cisplatin chemotherapy. (cnbc.com)
- Many testicular cancer survivors experience hearing loss after cisplatin-based chemotherapy, according to researchers at Indiana University. (news-medical.net)
- The researchers, led by Lois B. Travis, M.D., Sc.D., the Lawrence D. Einhorn Professor of Cancer Research at the IU School of Medicine and a researcher at the Indiana University Melvin and Bren Simon Cancer Center, studied for the first time the cumulative effects of cisplatin-based chemotherapy on hearing levels in testicular cancer survivors through comprehensive audiometry measurements. (news-medical.net)
- They indicate that it will be important to follow patients given cisplatin-based chemotherapy long term to better understand the extent to which the natural aging process may further add to hearing deficits, as it does in the general population. (news-medical.net)
- Our findings suggest that health care providers should, at a minimum, annually query patients who have received cisplatin-based chemotherapy about their hearing status, consulting with audiologists as indicated. (news-medical.net)
- The researchers found that the sugar was abundant in the cells of invasive bladder cancers that were previously treated but did not respond to the standard chemotherapy drug, cisplatin . (medindia.net)
- The chemotherapy drug cisplatin is often administered before surgical treatment to reduce the size of cancer. (medindia.net)
- One of the most effective chemotherapy drugs against cancer is cisplatin because it attaches to cancer DNA and disrupts repair. (innovations-report.com)
- Delayed administration of sodium thiosulfate after cisplatin chemotherapy may prevent treatment-related hearing loss in children with standard-risk hepatoblastoma without affecting survival outcomes, according to a study published online June 21 in the New England Journal of Medicine . (doctorslounge.com)
- WEDNESDAY, June 27, 2018 (HealthDay News) -- Delayed administration of sodium thiosulfate after cisplatin chemotherapy may prevent treatment-related hearing loss in children with standard-risk hepatoblastoma without affecting survival outcomes, according to a study published online June 21 in the New England Journal of Medicine . (doctorslounge.com)
- Cisplatin (CDDP)-based combination chemotherapy remains the mainstream treatment for advanced bladder cancer. (urotoday.com)
- Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all? (biomedsearch.com)
- The standard of care for resected stage II - IIIA non-small-cell lung cancer includes adjuvant chemotherapy based on the results of randomized trials using cisplatin regimens. (biomedsearch.com)
- However, long-term results of the International Adjuvant Lung Cancer Trial evaluating adjuvant cisplatin-based chemotherapy in resected non-small-cell lung cancer indicated a possible late adjuvant chemotherapy-related over-mortality. (biomedsearch.com)
- In the knowledge of late adjuvant chemotherapy-related over-mortality it is therefore critical to identify subsets of patients who would or would never benefit from adjuvant cisplatin. (biomedsearch.com)
- Despite highly effective cisplatin-based chemotherapy, around 20% of patients with metastatic disease will still die from the disease. (rug.nl)
- Evaluation of exposures to healthcare personnel from cisplatin during a mock demonstration of intra-operative intraperitoneal chemotherapy administration. (cdc.gov)
- In preparation for a clinical trial in which chemotherapy would be administered intraoperatively, the question of exposure to healthcare personnel arose, therefore, the purpose of this study was to perform an evaluation of healthcare personnel exposure to cisplatin during a mock demonstration of intraperitoneal chemotherapy administration. (cdc.gov)
- Chemotherapy is considered as the standard treatment for patients with advanced or recurrent cervical cancer, and cisplatin appears to treat the disease effectively. (dovepress.com)
- Nausea and vomiting: cisplatin is one of the most emetogenic chemotherapy agents, but this symptom is managed with prophylactic antiemetics (ondansetron, granisetron, etc.) in combination with corticosteroids. (wikipedia.org)
Reduced cisplatin-induced2
- Concomitant treatment with cilastatin reduced cisplatin-induced changes. (biomedsearch.com)
- green coffee reduced cisplatin-induced renal apoptosis. (scirp.org)
Acquired resistance1
- The clinically acquired resistance can be caused by decreased drug accumulation which includes reduced uptake or increased efflux of cisplatin, increased drug detoxification by cellular thiols, increased DNA repair or tolerance of cisplatin-damaged DNA and the ability of the cancer cells to evade cisplatin-induced cell death. (hindawi.com)
Effects of cisplatin10
- There are many options to help minimize or prevent the side effects of cisplatin. (chemocare.com)
- Common neurological side effects of cisplatin include visual perception and hearing disorder, which can occur soon after treatment begins. (wikipedia.org)
- What are the possible side effects of cisplatin? (cigna.com)
- Hearing problems and loss of balance are more likely to occur in children, who are usually more sensitive to the effects of cisplatin. (mayoclinic.org)
- These are not all the possible side effects of Cisplatin. (rxlist.com)
- No data were available to evaluate the teratogenic potential or the mutagenicity or chromosomal effects of cisplatin in humans. (inchem.org)
- Camel milk has protective effects against the clastogenic and cytotoxic effects of cisplatin. (greenmedinfo.com)
- For patients treated with cisplatin-based regimens for other types of cancer, it might also influence a physician to offer an alternative to those patients found to be genetically susceptible to the ototoxic effects of cisplatin after carefully weighing the risks and benefits of alternative treatments. (news-medical.net)
- OBJECTIVE: The purpose of this study was to investigate whether resveratrol adds to the growth inhibitory effects of cisplatin and doxorubicin on ovarian and uterine cancer cells and to evaluate whether resveratrol diminishes the cardiac toxicity of doxorubicin in rodent heart. (greenmedinfo.com)
- The common side-effects of cisplatin usage are generally induced by oxidative stress due to strong electrophilic nature of activated cisplatin ( 3 ). (frontiersin.org)
Administration of cisplatin7
- An ultimate goal is to use the genetic results to develop effective agents that will protect the ear during the administration of cisplatin. (news-medical.net)
- Extra intravenous fluid is given prior to and following administration of cisplatin to reduce side effects to the kidneys. (unm.edu)
- Kidney function tests and some electrolyte levels may be taken prior to each administration of cisplatin. (unm.edu)
- The extracellular levels of HMGB1, TNF-α and IFN-γ were also significantly decreased by the administration of cisplatin. (mdpi.com)
- The administration of cisplatin reduced the cytoplasmic levels of HMGB1 and increased nuclear HMGB1 levels in vitro and in vivo . (mdpi.com)
- This was the first study evaluating the exposure of healthcare personnel to the administration of cisplatin intra-operatively. (cdc.gov)
- After the intravenous administration of cisplatin, abnormal motor activity was produced in the involved vagus nerve and in the involved serotonergic neurons via another pathway. (sigmaaldrich.com)
Nephrotoxicity11
- The success of cisplatin therapy is compromised due to dose-limiting toxicity, especially nephrotoxicity as well as resistance by tumor cells to cisplatin. (hindawi.com)
- It has many similarities to human cisplatin nephrotoxicity, which are mentioned in the paper. (hindawi.com)
- Thymoquinone and curcumin combination protects cisplatin-induced kidney injury, nephrotoxicity. (greenmedinfo.com)
- Thymoquinone and curcumin combination protects cisplatin-induced kidney injury, nephrotoxicity by attenuating NFκB, KIM-1 and ameliorating Nrf2/HO-1 signalling. (greenmedinfo.com)
- In summary, Tq + Cur had protective effects on cisplatin-induced nephrotoxicity and renal injury, which could be mediated by up-regulation of survival signals like Akt, Nrf2/HO-1 and attenuation of KIM-1, NFκB. (greenmedinfo.com)
- Effect of short hydration on cisplatin-induced nephrotoxicity in cancer patients: A retrospective study. (springer.com)
- A major area in cancer therapy is the search for protective strategies against cisplatin-induced nephrotoxicity. (biomedsearch.com)
- Effect of TNF-α inhibitors on cisplatin nephrotoxicity. (jci.org)
- G1: control negative group was received isotonic saline (0.5 ml, i.p.) for 30 consecutive days, G2: sham operated group mice were received green coffee extract in water (40 mg/kg/day) for 30 consecutive days, animals of G3 and G4 were administered cisplatin (8 mg/kg/day, i.p.) at 10th day, which is well known to produce significant nephrotoxicity in rats. (scirp.org)
- Cisplatin alone, 90 mg/m 2 body surface area intraperitoneally, produced nephrotoxicity. (annals.org)
- medical citation needed] Cisplatin has a number of side effects that can limit its use: Nephrotoxicity (kidney damage) is a major concern. (wikipedia.org)
Toxicity11
- 2 SUMMARY The principal target organ for cisplatin toxicity is the kidney. (inchem.org)
- Cisplatin is usually administered in hospital and the administering clinician must monitor the patient for any signs and symptoms of toxicity. (inchem.org)
- Cumulative renal toxicity associated with cisplatin is severe. (nih.gov)
- Another active area of research has been to develop analogs of cisplatin to minimize toxicity and circumvent cisplatin resistance. (hindawi.com)
- Conclusions: CCRT with daily low-dose cisplatin for locally advanced stage III NSCLC resulted in promising overall survival (3-year survival rate of 52% and 5-year survival rate of 40%) with low toxicity. (mendeley.com)
- An additional 63 patients were randomized to MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) every 4 weeks, but this arm was closed prematurely due to excessive toxicity and did not yield data for presentation. (cancernetwork.com)
- This study evaluates the protective effects of Thymoquinone (Tq) and Curcumin (Cur) in models of cisplatin-induced renal toxicity. (greenmedinfo.com)
- This is a phase I dose escalation study of cisplatin and radiation to determine the toxicity of this combined treatment and establish an MTD. (knowcancer.com)
- Resveratrol adds to the growth inhibitory/anticancer activity of cisplatin and doxorubicin in vitro and protects against doxorubicin-induced cardiac toxicity both in vitro and in mice. (greenmedinfo.com)
- However, in addition to the efforts against to its toxicity, the amelioration of cisplatin sensitivity is an important point in treatment of cervical cancer. (frontiersin.org)
- Multiple mechanisms contribute to renal toxicity following exposure to cisplatin. (scirp.org)
Apoptosis17
- [9] While triggering apoptosis through interfering with DNA replication remains the primary mechanism of cisplatin, this has not been found to contribute to neurological side effects. (wikipedia.org)
- We have discussed various steps, including the entry of cisplatin inside cells, DNA repair, drug detoxification, DNA damage response, and regulation of cisplatin-induced apoptosis by protein kinases. (hindawi.com)
- Cisplatin, like many other chemotherapeutic drugs, can induce apoptosis. (hindawi.com)
- Thus, the signaling pathways that regulate apoptosis have significant impact on deciding cellular responsiveness to cisplatin. (hindawi.com)
- However, TMRM staining intensity, a marker of mitochondrial membrane potential, was decreased in immature oocytes from cisplatin treated mice compared to saline treated controls, consistent with the induction of apoptosis. (doaj.org)
- Phenotypic responses to cisplatin were quantified with respect to cell number, proliferation rate and apoptosis, and then compared with the epithelial or mesenchymal status. (nature.com)
- Overall, our results suggest that, in epithelial-like ovarian cancer cells, NF-κB activation by cisplatin may lead to defective apoptosis, preferential proliferation arrest and a consequential decreased sensitivity to cisplatin. (nature.com)
- Cisplatin (cis-diamminedichloroplatinum [II]) is a platinum compound that forms DNA adducts, which are subsequently involved in the activation of various signal transduction pathways involved in DNA damage recognition, DNA repair, cell cycle arrest and apoptosis. (nature.com)
- Furthermore, considerable evidence indicates that mutated p53 plays a significant role in the development of cisplatin resistance since several genes implicated in drug resistance and apoptosis (e.g. mismatch repair, bcl-2, high mobility group proteins, DNA polymerases alpha and beta, PCNA, and insulin-like growth factor) are known to be regulated by the p53 oncoprotein. (nih.gov)
- Tq + Cur combination synergistically reduced the proliferation inhibition of HEK-293 cells resulted from cisplatin treatment and brought down cisplatin-induced apoptosis in these cells.studies revealed serum levels of BUN, creatinine, CK and pro-inflammatory cytokines like TNF-α, IL-6 and MRP-1 to be elevated in the cisplatin-treated group while reducing glomerular filtration rate. (greenmedinfo.com)
- NP mediated controlled release of Platin-M and subsequent reduction of this prodrug to cisplatin allowed cross-links to be formed with the mitochondrial DNA, which have no nucleotide excision repair system, forcing the overactive cancer cells to undergo apoptosis. (rsc.org)
- Our observations revealed that EGCG increases the sensitization of cisplatin to cervical cancer cells by inhibiting cell survival and inducing apoptosis. (frontiersin.org)
- Two mTORC1/2 inhibitors, AZD8055 and MLN0128, strongly enhanced cisplatin-induced apoptosis in all tested TC cell lines. (rug.nl)
- Inhibition of caspase activity by caspase-9 inhibitor (z-LEHD-fmk) or by overexpression of Bcl-2 potently inhibited apoptosis induced by cisplatin. (cdc.gov)
- Since Bcl-2 is overexpressed in many cancer cell types and resistance to cisplatin-induced apoptosis is a major limitation for effective therapy, the knowledge from this study could be beneficial to the design of more effective therapy for cancer treatment. (cdc.gov)
- Green coffee administration in cisplatin-induced renal apoptosis groups produced significant lower levels of BUN, creatinine, uric acid and H 2 O 2 (24.4 ± 4.14, 1.730 ± 0.2830, 5.50 ± 0.850 and 0.51 ± 0.12 respectively) as compared with cisplatin-induced renal apoptosis group not administrated green coffee (27.4 ± 6, 2.04 ± .31, 7.00 ± 1.25 and 1.1 ± 0.16 respectively). (scirp.org)
- Green coffee improved the general condition of cisplatin-induced renal apoptosis rats due to its antioxidant and anti-apoptotic effects. (scirp.org)
Injection15
- Cisplatin may cause severe allergic reactions, especially if you have received more than one dose of cisplatin injection. (medlineplus.gov)
- Cisplatin injection comes as a solution (liquid) to be injected over 6 to 8 hours intravenously (into a vein) by a doctor or nurse in a medical facility. (medlineplus.gov)
- tell your doctor and pharmacist if you are allergic to cisplatin, carboplatin (Paraplatin), any other medications, or any of the ingredients in cisplatin injection. (medlineplus.gov)
- 1.7 Presentation/formulation Cisplatin powder for injection: Yellowish-white freeze-dried cake in clear glass vials containing 10mg or 50mg cisplatin. (inchem.org)
- Cisplatin solution for injection: Clear, practically colourless solution in amber glass vials containing cisplatin 1mg/ml, sodium chloride 9mg/ml and mannitol 1mg/ml with a pH of 3.5-4.0. (inchem.org)
- Cisplatin Injection is a clear, colorless, sterile aqueous solution. (nih.gov)
- Each 100 mL amber vial of Cisplatin Injection contains: 1 mg per mL cisplatin USP, 9 mg per mL sodium chloride, hydrochloric acid and/or sodium hydroxide to adjust pH, and water for injection USP to a final volume of 50 mL and 100 mL, respectively. (nih.gov)
- The pH range of Cisplatin Injection is 3.8 to 5.9. (nih.gov)
- Call your doctor if you miss an appointment for your cisplatin injection. (cigna.com)
- Anaphylactic-like reactions to cisplatin (cisplatin injection) have been reported. (rxlist.com)
- Cisplatin Injection (cisplatin injection (cisplatin (cisplatin injection) injection) ) is a sterile aqueous solution, available in 50, 100 and 200 mL multiple dose vials, each mL containing 1 mg of cisplatin (cisplatin injection) and 9 mg sodium chloride in water for injection. (rxlist.com)
- Cisplatin (cisplatin injection) (cis-diamminedichloroplatinum) is a heavy metal complex containing a central atom of platinum surrounded by two chloride atoms and two ammonia molecules in the cis position. (rxlist.com)
- An established combination consists of cisplatin (cisplatin injection) and cyclophosphamide. (rxlist.com)
- PLATINOL® (cisplatin injection) infusion concentrate is a clear, colorless, sterile aqueous solution available in amber vials. (rxlist.com)
- A formulation for preparing Cisplatin 1-mg/mL Injection. (ijpc.com)
Carboplatin4
- Care must be taken to avoid inadvertent cisplatin overdose due to confusion with carboplatin or prescribing practices that fail to differentiate daily doses from total dose per cycle. (nih.gov)
- You should not receive this medication if you are allergic to cisplatin or similar medications such as carboplatin (Paraplatin) or oxaliplatin (Eloxatin). (cigna.com)
- In addition to cisplatin, its analogs, such as carboplatin and oxaliplatin, are also currently being used in the clinic. (hindawi.com)
- Platinum-based anticancer agents such as cisplatin and carboplatin display a broad range of activities against solid tumors ( 11 , 12 ). (mcponline.org)
Drug cisplatin4
- It was found that tetracycline-resistant bacteria expressing the TnlO gene of tetracycline resistance, upon induction with tetracycline, became extremely susceptible to destruction by the DNA-damaging anti-cancer drug cisplatin. (mit.edu)
- By targeting mitochondria with the anticancer drug cisplatin, chemists have developed a new way to kill cancer cells that have shown resistance to cisplatin. (scitechdaily.com)
- The Saccharomyces cerevisiae PP4R3 ortholog Psy2 was identified previously in a screen for sensitivity to the DNA-damaging agent and anticancer drug cisplatin. (mcponline.org)
- Interestingly deletion of the yeast PP4R3 ortholog PSY2 was demonstrated previously to elicit hypersensitivity to the DNA damage-inducing drug cisplatin ( 10 ). (mcponline.org)
Plus cisplatin8
- GOG 179, a multicenter phase II trial, showed the combination of topotecan (Hycamtin) plus cisplatin to be superior in multiple outcome parameters over single-agent cisplatin in the treatment of recurrent or persistent cancer of the cervix, reported Harry J. Long, III, MD, associate professor of oncology, Mayo Clinic College of Medicine, Rochester, Minnesota. (cancernetwork.com)
- Treatment with topotecan plus cisplatin improved not only response rates and progression-free survival but also overall survival, and is the first controlled trial to show this. (cancernetwork.com)
- Combination therapy with pemetrexed plus cisplatin is the standard first line therapy for malignant mesothelioma, but results in a median overall survival of only 12.1 months. (mesothelioma.com)
- Combination of SS1(dsFv)PE38 with pemetrexed plus cisplatin could result in improved outcomes for patients with mesothelioma. (mesothelioma.com)
- To determine the MTD of SS1(dsFv)PE38 that can be safely administered in combination with pemetrexed plus cisplatin in patients with mesothelioma. (mesothelioma.com)
- To observe anti-tumor activity, if any of SS1(dsFv)PE38 in combination with pemetrexed plus cisplatin. (mesothelioma.com)
- Docetaxel plus cisplatin might be an effective therapeutic option for thymoma-associated MG patients complicated with hypertension /diabetes post thymectomy without worsening thymoma and hypertension / diabetes. (degruyter.com)
- Fluorouracil plus cisplatin and radiation twice a day (FCT) is an established chemoradiation (CRT) regimen for selective bladder-sparing treatment of muscle-invasive bladder cancer. (bioportfolio.com)
Receive cisplatin5
- You should not receive cisplatin if you have kidney disease, bone marrow suppression, or hearing loss. (cigna.com)
- Before you receive cisplatin, tell your doctor about all other medications you use. (cigna.com)
- You may be given IV fluids for 8 to 12 hours before you receive cisplatin. (cigna.com)
- After 1 week of imatinib mesylate and folic acid, you will receive cisplatin and pemetrexed by IV infusion. (knowcancer.com)
- Cats are vulnerable to severe pulmonary (lung) side effects and cannot receive cisplatin. (marvistavet.com)
CDDP4
- In some cases, health care professionals may use the trade name Platinol® and Platinol®-AQ, or other names such as CDDP, when referring to the generic drug name cisplatin. (chemocare.com)
- Chemoresistance is one key factor for the failure of cisplatin (CDDP)-based therapy in colorectal cancer (CRC). (dovepress.com)
- Cisplatin (cis-diamminedichloroplatinum II, CDDP), an inorganic platinum compound, is one of the effective chemotherapeutic agents in the treatment of several types of cancer, including cervical carcinomas ( 1 ). (frontiersin.org)
- Cisplatin (cis-diamminedichloroplatinum (II), CDDP) is widely used as a chemotherapeutic drug used in the treatment of numerous human cancers, including bladder, head and neck, ovarian and testicular cancers, lung, and breast. (scirp.org)
Ovarian11
- Cisplatin is used together with other medications to treat bladder cancer, testicular cancer, or ovarian cancer. (cigna.com)
- Cisplatin has been used as a first-line therapy for several cancers, including testicular, ovarian, cervical, head, and neck and small-cell lung cancers either alone or in combination with other anticancer agents. (hindawi.com)
- Conclusions These findings suggest that mitochondrial dysfunction may contribute to the depletion of the ovarian reserve caused by cisplatin, but long-term impacts on mitochondria may be minimal as those immature oocytes that survive cisplatin treatment develop into mature oocytes with normal mitochondrial parameters. (doaj.org)
- Chemoresistance to platinums, such as cisplatin, is of critical concern in the treatment of ovarian cancer. (nature.com)
- The current study explored the connection between cellular responses to cisplatin and EMT in ovarian cancer. (nature.com)
- Expression microarrays were utilized to estimate the EMT status as a binary phenotype, and the transcriptional responses of 46 ovarian cancer cell lines to cisplatin were measured at dosages equivalent to 50% growth inhibition. (nature.com)
- Ovarian cancer cell lines with an epithelial status exhibited higher resistance to cisplatin treatment in the MTS assay than those with a mesenchymal status. (nature.com)
- Cisplatin is a prescription medicine used to treat the symptoms of cancer in the testicles (Metastatic Testicular Tumors), bladder (Advanced Bladder Cancer ) and ovaries (Metastatic Ovarian Carcinoma). (rxlist.com)
- Cisplatin has been used since the 1970s primarily in the treatment of testicular and ovarian cancer, often in combination with other antineoplastic drugs. (inchem.org)
- Bitter melon extract functions as a natural AMPK activator in the inhibition of ovarian cancer cell growth and might be useful as a supplement to improve the efficacy of cisplatin. (greenmedinfo.com)
- RUDN biochemists studied the mechanism of drug resistance development in ovarian cancer cells under treatment with cisplatin. (eurekalert.org)
Testicular cancer3
- Although this study was conducted in patients with testicular cancer, the authors point out that the general conclusions are likely applicable to patients with other types of adult-onset cancers that are commonly treated with cisplatin. (news-medical.net)
- The researchers pointed out that because alterations in the highly successful testicular cancer regimens are unlikely for patients with advanced disease, their results underscore the importance of ongoing research aimed at the identification of genetic variants associated with cisplatin-related ototoxicity. (news-medical.net)
- The aim of this study was to explore the use of kinase inhibitors to sensitize testicular cancer cells to cisplatin treatment. (rug.nl)
Sensitivity8
- How cells respond to cisplatin-induced DNA damage plays a critical role in deciding cisplatin sensitivity. (hindawi.com)
- Furthermore, the identification of oncogenes involved in cisplatin resistance has already led to in vitro approaches which successfully inactivated these genes using ribozymes or antisense oligodeoxynucleotides, thus restoring cisplatin sensitivity. (nih.gov)
- Previously, it was showed that cisplatin resistant TGCTs overexpress ALDH isoforms and inhibition of ALDH activity by disulfiram is associated with reconstitution of cisplatin sensitivity. (clinicaltrials.gov)
- Cisplatin-resistant TGCTs exhibited increased sensitivity to ALDH inhibitor disulfiram in vitro. (clinicaltrials.gov)
- Investigators hypothesize that inactivation of ALDH by disulfiram recover cisplatin sensitivity in patients with progressing or relapsing germ cell cancer. (clinicaltrials.gov)
- A ) Effect of CHIP overexpression and MAST1 knockdown on cisplatin sensitivity and MAST1 protein level. (jci.org)
- B ) Effect of MAST1 WT rescue expression on cisplatin sensitivity and MAST1 protein level in cells with CHIP overexpression and MAST1 knockdown. (jci.org)
- miR-1271 enhances the sensitivity of colorectal cancer cells to cisplatin. (medworm.com)
Intravenously9
- Cisplatin is administered through a vein (intravenously or IV) as an infusion. (chemocare.com)
- Cisplatin is administered intravenously as short-term infusion in normal saline for treatment of solid malignancies. (wikipedia.org)
- You have cisplatin as a drip into your bloodstream (intravenously). (cancerresearchuk.org)
- Patients with advanced, unresectable NETs of pancreatic, gastrointestinal foregut or unknown primary site were randomised to receive three-weekly capecitabine (Cap) 625 mg/m(2) twice daily orally, streptozocin (Strep) 1.0 g/m(2) intravenously on day 1, with or without cisplatin (Cis) 70 mg/m(2) intravenously on day 1. (nih.gov)
- Cisplatin can be given intravenously (into a vein), or intraperitoneally (into the peritoneum of the abdominal cavity). (unm.edu)
- Cisplatin is usually used intravenously and is given in conjunction with a process called "diuresis. (marvistavet.com)
- Cisplatin given intravenously produced abnormal motor activity that lasted up to 5 h. (sigmaaldrich.com)
- In normal intact dogs with resection of the vagus nerve that were administered kytril, cisplatin given intravenously did not produce abnormal motor activity. (sigmaaldrich.com)
- Cisplatin is administered intravenously as short-term infusion in normal saline for treatment of solid and haematological malignancies. (wikipedia.org)
Ototoxicity11
- NEW YORK (Reuters Health) - Sodium thiosulfate can be used to prevent cisplatin-induced ototoxicity in children and adolescents with cancer, according to a new clinical-practice guideline. (medscape.com)
- Cisplatin-induced ototoxicity is permanent and progressive. (medscape.com)
- Dr. Sung and colleagues on a multidisciplinary, multinational panel used a systematic review of 27 randomized trials to develop a guideline for the prevention of cisplatin-induced ototoxicity in children and adolescents with cancer. (medscape.com)
- The authors strongly recommend against using amifostine or sodium diethyldithiocarbamate for the prevention of cisplatin-induced ototoxicity in these patients, based on high-quality and low-quality evidence, respectively. (medscape.com)
- Based on low-quality evidence, the guideline strongly discourages both using intratympanic middle-ear therapy and altering cisplatin-infusion duration, as a means in itself, to prevent ototoxicity in these patients. (medscape.com)
- Cite this: New Guideline Recommends Sodium Thiosulfate to Prevent Cisplatin-Induced Ototoxicity - Medscape - Jan 16, 2020. (medscape.com)
- This study demonstrated that intratympanic administration of 6% OTO-104 protected against ototoxicity observed following both acute and repeat administration of the chemotherapeutic agent cisplatin. (cnbc.com)
- Currently, no drugs or therapeutic strategies have been approved for the treatment of cisplatin-induced ototoxicity by the FDA.Purpose: The purpose of this study was to investigate the otoprotective effects of dexamethasone (DEX)-loaded silk-polyethylene hydrogel (DEX-SILK) following round window membrane administration in the cisplatin-induced ototoxicity mouse model.Methods: The morphology, gelation kinetics, viscosity and secondary structure of the DEX-SILK hydrogel were analyzed. (doaj.org)
- DEX-SILK (5-60 ng/ml) exhibited significant protective effects against cisplatin-induced cellular ototoxicity and notably reduced the production of reactive oxygen species (ROS). (doaj.org)
- Other drugs (such as the aminoglycoside antibiotic class) may also cause ototoxicity, and the administration of this class of antibiotics in patients receiving cisplatin is generally avoided. (wikipedia.org)
- The ototoxicity of both the aminoglycosides and cisplatin may be related to their ability to bind to melanin in the stria vascularis of the inner ear or the generation of reactive oxygen species. (wikipedia.org)
Respond to cisplatin3
- However, patients who initially respond to cisplatin therapy often develop resistance to the drug during the course of the treatment. (hindawi.com)
- Tumor cells, in contrast to normal cells, respond to cisplatin exposure with transient gene expression to protect or repair their chromosomes. (nih.gov)
- However, many patients do not respond to cisplatin and need more treatment options. (medindia.net)
Activity of cisplatin3
- The antitumor activity of cisplatin is believed to be due to its interaction with chromosomal DNA [ 4 ]. (hindawi.com)
- HeLa cells were used to control the effect of cilastatin on the tumoricidal activity of cisplatin. (biomedsearch.com)
- Cilastatin attenuates cisplatin-induced cell death in proximal tubular cells without reducing the cytotoxic activity of cisplatin in tumor cells. (biomedsearch.com)
Effectiveness of cisplatin3
- There is no relationship between the presence or severity of Cisplatin side effects and effectiveness of cisplatin. (chemocare.com)
- Read user comments about the side effects, benefits, and effectiveness of cisplatin intravenous. (webmd.com)
- Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic cancer cell lines and in rodent heart. (greenmedinfo.com)
Intravenous6
- Cisplatin infusion is given via a drip into a vein (intravenous infusion). (netdoctor.co.uk)
- Day 1 - Intravenous (through a vein) infusions of pemetrexed and cisplatin. (mesothelioma.com)
- Dose Escalation: Begin with Level 1 dose of enzalutamide (orally), with standard doses of cisplatin and gemcitabine via intravenous (IV). (clinicaltrials.gov)
- Diuresis employs intravenous fluids to perfuse the kidneys and assist them in their toxin filtration duties which means your pet will have to be hospitalized on the day of treatment and receive intravenous fluids for several hours along with the intravenous cisplatin. (marvistavet.com)
- Seventeen patients with intraperitoneal tumors were treated by 4-hour intraperitoneal dialysis with cisplatin alone, or in combination with an intravenous neutralizing agent, sodium thiosulfate. (annals.org)
- When intraperitoneal cisplatin therapy was combined with intravenous thiosulfate treatment, the dose of cisplatin could be escalated to 270 mg/m 2 body surface area without causing an increase in serum creatinine levels or undue myelosuppression. (annals.org)
Abstract2
- Abstract Background Cisplatin is a platinum-based chemotherapeutic that damages genomic DNA leading to cell death. (doaj.org)
- SAN DIEGO-For the first time, a combination regimen has shown improved survival over single-agent cisplatin (Platinol) for the treatment of advanced cervical cancer, according to the Gynecologic Oncology Group (GOG) protocol 179, which was presented at the 35th Annual Meeting of the Society of Gynecologic Oncologists (abstract 9). (cancernetwork.com)
Therapeutic4
- An understanding of how various signaling pathways regulate cisplatin-induced cell death should aid in the development of more effective therapeutic strategies for the treatment of cancer. (hindawi.com)
- An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer. (medindia.net)
- Furthermore, pharmaceutical inhibition of ITPKB displayed synergistic attenuation of tumor growth with cisplatin, suggesting ITPKB as a promising synthetic lethal target for cancer therapeutic intervention to overcome cisplatin resistance. (jci.org)
- Because HMGB1 is a powerful inflammatory mediator in many diseases, the aim of this study is to evaluate the therapeutic effect of cisplatin acute liver failure. (mdpi.com)
Doses11
- Doses of cisplatin which produce changes in renal function may cause no histopathological changes. (inchem.org)
- Plasma concentrations of the parent compound, cisplatin, decay monoexponentially with a half-life of about 20 to 30 minutes following bolus administrations of 50 or 100 mg/m 2 doses. (nih.gov)
- In mice, high doses of cisplatin can induce embryolethality. (inchem.org)
- Consequently, the protocols among studies differ significantly (i.e., from low nephrotoxic to extremely high lethal doses of cisplatin). (hindawi.com)
- They found that increasing doses of cisplatin were associated with increased hearing loss at most of the tested frequencies, involving 4, 6, 8, 10, and 12 kHz. (news-medical.net)
- 400 mg/m2 cisplatin) doses. (unboundmedicine.com)
- At cumulative doses of cisplatin higher than 300 mg/m2 the patients lost distal tendon and H-reflexes and displayed reduced vibration sense in the feet and the fingers. (unboundmedicine.com)
- Motor conduction studies, autonomic function and warm and cold temperature sensation remained unchanged at all doses of cisplatin treatment. (unboundmedicine.com)
- The results of these studies are consistent with degeneration of large sensory neurons whereas there was no evidence of distal axonal degeneration even at the lowest toxic doses of cisplatin. (unboundmedicine.com)
- The dosing regimen of cisplatin and gemcitabine will be at standard doses of Gemcitabine at 1000 mg/m^2 IV on days 1, 8 and cisplatin at 70 mg/m2 IV on day 1, repeated every 21 days for total of 6 cycles. (clinicaltrials.gov)
- Dose Expansion: Enzalutamide at recommended dose level with standard doses of cisplatin and gemcitabine. (clinicaltrials.gov)
Fluorouracil5
- Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. (nih.gov)
- Phase 2 studies suggest that the standard regimen of cisplatin and fluorouracil (PF) plus docetaxel (TPF) improves outcomes in squamous-cell carcinoma of the head and neck. (nih.gov)
- Cisplatin should not replace mitomycin when given with fluorouracil and radiotherapy in the primary treatment of localized anal canal carcinoma," they concluded. (medpagetoday.com)
- Combination cisplatin and 5-fluorouracil-induced takotsubo cardiomyopathy in oropharyngeal cancer: A case report. (springer.com)
- Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. (bioportfolio.com)
Cytotoxic2
- Further complicating these mechanisms of platinum resistance, growing evidence has suggested an association between epithelial-mesenchymal transition (EMT) and cellular resistance to many cytotoxic reagents, including cisplatin. (nature.com)
- Spreckelmeyer S, Orvig C, Casini A. Cellular Transport Mechanisms of Cytotoxic Metallodrugs: An Overview beyond Cisplatin. (mdpi.com)
Bladder cancer3
- Cisplatin is also used alone or in combination with other medications to treat bladder cancer that can not be treated with surgery or radiation therapy alone. (medlineplus.gov)
- The main purpose of this study is to find out the dose of enzalutamide that can be safely given with gemcitabine and cisplatin in patients with advanced bladder cancer. (clinicaltrials.gov)
- The cohort expansion will then be done by enrolling 12 patients with stage IV bladder cancer, who express androgen receptor (AR) staining of 1+ and above by immunohistochemistry (IHC), to determine the safety and tolerability of cisplatin and gemcitabine with the recommended dose level of enzalutamide (80 mg or 160 mg, depending upon the safety results from dose escalation part) in this expanded cohort of patients with AR + bladder cancer. (clinicaltrials.gov)
Vinblastine1
- Autonomic neuropathy after treatment with cisplatin, vinblastine, and bleomycin for germ cell cancer. (bmj.com)
Prevention of cisplatin-induced2
- Therefore, cilastatin administration might represent a novel strategy in the prevention of cisplatin-induced acute renal injury. (biomedsearch.com)
- Our recent financing enables us to expand the scope of our development efforts, and the clinical evaluation of OTO-104 for the prevention of cisplatin-induced hearing loss is a priority based on the high unmet medical need, attractive market potential, and preclinical proof-of-concept presented in this publication," said David A. Weber, Ph.D., president and CEO of Otonomy. (cnbc.com)
Improved by cisplatin treatment1
- We found that cell viability and liver injury were greatly improved by cisplatin treatment. (mdpi.com)
Minutes of cisplatin administration1
- Patients may experience an allergic-type reaction within minutes of cisplatin administration consisting of wheezing, difficulty breathing and low blood pressure. (unm.edu)
Controlling cisplatin induced nausea1
- Dexamethasone and high dose metoclopramide: efficacy in controlling cisplatin induced nausea and vomiting. (bmj.com)
Clinical11
- This page contains brief information about cisplatin and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials. (cancer.gov)
- Find Clinical Trials for Cisplatin - Check for trials from NCI's list of cancer clinical trials now accepting patients. (cancer.gov)
- Cisplatin was indeed demonstrated to possess antitumor activity in a mouse model [ 3 ] and was first used in the clinical trial almost 30 years ago. (hindawi.com)
- Improved understanding of molecular factors for the development of cisplatin resistance may allow the prediction of clinical response to cisplatin-based treatment. (nih.gov)
- It is conceivable that these strategies, once transferred to a clinical setting, may have the potential to enhance the efficacy of cisplatin against a great variety of malignancies and thus more fully exploit the antineoplastic and curative potential of this drug. (nih.gov)
- Cisplatin rodent model has been recognized as a simple and reproducible model with high clinical relevance [ 9 ]. (hindawi.com)
- To evaluate clinical and pathologic responses in TNBC treated with preoperative cisplatin and paclitaxel. (clinicaltrials.gov)
- Originally my gyno oncologist treatment plan was 1x weekly for each of the 5 weeks of radiation.At Center closer to my home where I receive treatment says there was a new clinical trial that the showed no different results for most that received Cisplatin Week 1 and Week 4 of radiation. (cancer.org)
- TY - JOUR T1 - Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. (unboundmedicine.com)
- We have published hundreds of Cisplatin Gemcitabine Hydrochloride Radiation Therapy Pancreatic Cancer news stories on BioPortfolio along with dozens of Cisplatin Gemcitabine Hydrochloride Radiation Therapy Pancreatic Cancer Clinical Trials and PubMed Articles about Cisplatin Gemcitabine Hydrochloride Radiation Therapy Pancreatic Cancer for you to read. (bioportfolio.com)
- In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cisplatin Gemcitabine Hydrochloride Radiation Therapy Pancreatic Cancer Companies in our database. (bioportfolio.com)
Nausea1
- Nausea beginning six hours after treatment and persisting for another six hours is expected with use of cisplatin. (marvistavet.com)
Mechanism7
- We propose here a new mechanism of cisplatin resistance mediated by glutathione transferase (GST) P1-1, as a cisplatin-binding protein. (pnas.org)
- At this time, the mechanism of increased DNA damage formation and the mechanism underlying sensitization to cisplatin are still matters of speculation. (mit.edu)
- However, the molecular mechanism regulating MAST1 levels in cisplatin-resistant tumors is unknown. (jci.org)
- Our study not only uncovers the regulatory mechanism of MAST1 in tumors but also suggests a promising combinatorial therapy to overcome cisplatin resistance in human cancers. (jci.org)
- As other anti-cancer drugs, the mechanism of cisplatin action occurs by induction of cell death through DNA damage. (frontiersin.org)
- The detailed mechanism by which cells recognize and process cisplatin−DNA damage is of great interest. (mit.edu)
- Mechanism of gastrointestinal abnormal motor activity induced by cisplatin in conscious dogs. (sigmaaldrich.com)
Efficacy4
- Non-randomized, open-label, single center trial to assess efficacy (as measured by overall response rate (ORR) by RECIST 1.1 of disulfiram and cisplatin in patients with multiple relapsed/refractory germ cell tumors (GCTs). (clinicaltrials.gov)
- EGCG improved efficacy of cisplatin treatment in HeLa cells by regulating NFκB p65, COX-2, p-Akt, and p-mTOR pathways, whereas it increased the expression levels of Nrf2/HO-1 in combined therapy. (frontiersin.org)
- Use of antioxidant supplements may mitigate this side effect but also can reduce the efficacy of cisplatin against the cancer it is combatting. (marvistavet.com)
- However, resistance to cisplatin may develop, thus substantially compromising the efficacy of cisplatin to treat advanced or recurrent cervical cancer. (dovepress.com)
Protein9
- Cisplatin does not undergo the instantaneous and reversible binding to plasma proteins that is characteristic of normal drug-protein binding. (nih.gov)
- In addition, AP-2 transcription factors, modulated by protein kinase A, are also implicated in cisplatin resistance by regulating genes encoding for DNA polymerase beta and metallothionines. (nih.gov)
- Our results show that cisplatin can be inactivated by this protein with the aid of 2 solvent-accessible and reactive cysteines. (pnas.org)
- The research team studied the effect of the malaria protein - drug combo in mice, whose bladders were implanted with highly aggressive cancers that were resistant to treatment with cisplatin. (medindia.net)
- Because cisplatin binds covalently to protein, labeling remains strong through subsequent steps used in downstream mass cytometry staining protocols. (fluidigm.com)
- Recent studies have focused on the ability of cisplatin to retain the high mobility group box 1 (HMGB1) protein in cisplatin-DNA adducts, thereby preventing its release from the nucleus. (mdpi.com)
- Although the family of proteins that bind cisplatin 1,2- and 1,3-intrastrand cross-links has been identified, much less is known about cellular protein interactions with cisplatin interstrand cross-links (ICLs). (mit.edu)
- Cisplatin administration increased expression of the apoptotic protein caspase-3. (scirp.org)
- Using a combination of tandem affinity purification tagging and mass spectrometry, we characterized a novel, evolutionarily conserved protein phosphatase 4 (PP4)-containing complex (PP4cs, protein phosphatase 4, cisplatin-sensitive complex) that plays a critical role in the eukaryotic DNA damage response. (mcponline.org)
Infusion3
- Day one - you have etoposide as a drip (infusion) over an hour and cisplatin as a drip (infusion). (macmillan.org.uk)
- Before and/or after the cisplatin infusion, extra IV fluids are given and care is taken to ensure adequate hydration before both during and after cisplatin, to protect your kidney function. (chemocare.com)
- Cisplatin also has been used as an infusion into the abdominal cavity (contains the abdominal organs). (chemocare.com)
Cancer cells to cisplatin2
- Targeting hsp90B sensitized cancer cells to cisplatin predominantly through MAST1 destabilization. (jci.org)
- Targeting ITPKB with shRNA or its small-molecule inhibitor resulted in attenuation of NOX4 activity, imbalanced redox status, and sensitized cancer cells to cisplatin treatment in patient-derived xenografts. (jci.org)
Kidney6
- Cisplatin may cause serious kidney problems. (medlineplus.gov)
- To help understand mechanisms involved in the development of kidney injury, cisplatin rodent model has been developed. (hindawi.com)
- Given the complex pathogenesis of kidney injury, which involves both local events in the kidney and interconnected and interdependent systemic effects in the body, cisplatin rodent model is indispensable in the investigation of underlying mechanisms and potential treatment strategies of both acute and chronic kidney injury. (hindawi.com)
- Nowadays, 20-30% of patients develop acute kidney injury (AKI) after cisplatin treatment despite improvements in therapy [ 1 ]. (hindawi.com)
- The investigation of the development of CKI was not gaining any attention, although it was known that cisplatin can have long term effects on the structure and function of the rat kidney after single [ 10 - 12 ] or multiple [ 13 - 15 ] administration. (hindawi.com)
- Cisplatin can cause kidney damage. (marvistavet.com)
Therapy18
- Cisplatin is used combination with other medications to treat cancer of the testicles that has not improved or that has worsened after treatment with other medications or radiation therapy. (medlineplus.gov)
- Cisplatin is used alone or in combination with other medications to treat cancer of the ovaries (cancer that begins in the female reproductive organs where eggs are formed) that has not improved or that has worsened after treatment with other medications or radiation therapy. (medlineplus.gov)
- Slight changes in liver function and histopathology are also observed following cisplatin therapy. (inchem.org)
- Cisplatin side effects will improve after therapy is complete. (chemocare.com)
- In addition, cisplatin is used in Auger therapy . (wikipedia.org)
- Microbiota Reconstitution Restores Intestinal Integrity After Cisplatin Therapy. (moffitt.org)
- The study randomized 145 patients to single-agent cisplatin, 50 mg/m 2 every 3 weeks, and 148 patients to combination therapy with cisplatin 50 mg/m 2 on day 1 plus topotecan 0.75 mg/m 2 on days 1 to 3 every 3 weeks. (cancernetwork.com)
- The results were the most favorable in the 40% of patients who had not received prior cisplatin as a radiosensitizer, although prior cisplatin therapy did not hold up as an independent predictor in a multivariate analysis. (cancernetwork.com)
- To evaluate the performance of the HRD-LOH assay, the HRD-TAI assay, and the HRDLST assay, to predict pathologic response to cisplatin or taxane therapy in TNBC. (clinicaltrials.gov)
- Although Disulfiram (Antabuse) is an approved drug to support the treatment of chronic alcoholism, it may serve as an antitumor agent suitable for the drug repurposing in combination therapy in order to inhibit ALDH activity thus overcoming a cisplatin resistance in refractory TGCTs. (clinicaltrials.gov)
- Standard therapy for mesothelioma is a combination of the drugs pemetrexed and cisplatin. (mesothelioma.com)
- HOUSTON -- In patients with anal canal carcinoma, a rare malignancy, cisplatin-based induction therapy did not pan out, a randomized trial revealed. (medpagetoday.com)
- The authors reported colostomy rates of 10% with the mitomycin regimen and 19% with the cisplatin therapy ( P =0.02). (medpagetoday.com)
- This effect is used in cancer therapy, and cisplatin may operate on a similar principle. (eurekalert.org)
- To determine the maximum tolerated dose of cisplatin when given concurrently with radiation therapy for participants with Stage II or III breast cancer who have undergone breast conserving surgery. (knowcancer.com)
- We aimed to investigate the possible molecular pathways to potentiate cervical cancer cell (HeLa) growth inhibition by combination therapy of cisplatin and EGCG. (frontiersin.org)
- Here you can see the latest Cisplatin Gemcitabine Hydrochloride Radiation Therapy Pancreatic Cancer articles that have been published worldwide. (bioportfolio.com)
- You can also find out about relevant Cisplatin Gemcitabine Hydrochloride Radiation Therapy Pancreatic Cancer Drugs and Medications on this site too. (bioportfolio.com)
Cervical cancer2
- Herein, we have demonstrated that EGCG works synergistic with cisplatin in inhibiting growth of cervical cancer cells. (frontiersin.org)
- In this article, we systematically review the recent literature and summarize the recent advances in our understanding of the molecular mechanisms underlying cisplatin resistance in cervical cancer. (dovepress.com)
Generation of reactive oxygen1
- Treatment of the cells with cisplatin induced rapid generation of reactive oxygen species (ROS) and a concomitant increase in apoptotic cell death. (cdc.gov)
Sodium5
- Recent studies have shown that cisplatin noncompetitively inhibits an archetypal, membrane-bound mechanosensitive sodium-hydrogen ion transporter known as NHE-1 . (wikipedia.org)
- In 33 percent of children in the cisplatin-sodium thiosulfate group and 63 percent in the cisplatin-alone group, hearing loss of grade 1 or higher occurred, which indicated a 48 percent lower incidence of hearing loss in the cisplatin-sodium thiosulfate group. (doctorslounge.com)
- At a median of 52 months of follow-up, the three-year rates of event-free survival were 82 percent in the cisplatin-sodium thiosulfate group and 79 percent in the cisplatin-alone group, while the three-year rates of overall survival were 98 percent and 92 percent, respectively. (doctorslounge.com)
- We found that the delayed administration of sodium thiosulfate resulted in a significantly lower incidence of cisplatin-induced hearing loss, with no evidence of tumor protection," conclude the authors. (doctorslounge.com)
- Inhibition of ROS by the antioxidant enzyme catalase or glutathione peroxidase (H2O2 scavenger), but not by superoxide dismutase (O2*- scavenger) or sodium formate (OH* scavenger), inhibited cisplatin-induced Bcl-2 downregulation. (cdc.gov)
Tumors5
- Cisplatin is one of the most effective anticancer agents widely used in the treatment of solid tumors. (hindawi.com)
- Since its approval by the Food and Drug administration in 1978, cisplatin continues to be one of the most effective anticancer drugs used in the treatment of solid tumors. (hindawi.com)
- Indeed, cisplatin is one of the most successful anticancer agents, effective against a wide range of solid tumors. (pnas.org)
- To see if SS1(dsFV)PE38 given with pemetrexed and cisplatin has any effect on patients tumors. (mesothelioma.com)
- 5Department of Otology and Laryngology, Eaton-Peabody Laboratory, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Decibel Therapeutics, Boston, MA, 02215, USABackground: Cisplatin is an extensively used anti-neoplastic agent for the treatment of various solid tumors. (doaj.org)
Platinol-AQ1
- Cisplatin is the generic name for the trade name drug Platinol® and Platinol®-AQ. (chemocare.com)
Dose of cisplatin2
- This treatment takes 1 to 3 hours depending on the dose of Cisplatin. (healthwise.net)
- The researchers found that every 100 mg/m2 increase in cumulative dose of cisplatin resulted in a 3.2 dB impairment in hearing. (news-medical.net)
Cycles of cisplatin2
- After 6 cycles of cisplatin and Teysuno, you may be able to continue to take Teysuno for as long as it works. (cancerresearchuk.org)
- After you complete 6 treatment cycles of cisplatin and pemetrexed, you will continue to take imatinib mesylate tablets every day up to 1 month after the 6 treatment cycles. (knowcancer.com)
Known that cisplatin1
- Although it is well known that cisplatin causes a sensory neuropathy, the primary site of involvement is not established. (unboundmedicine.com)
Response to cisplatin1
- Your doctor will order certain tests before, during, and after your treatment to check your body's response to cisplatin. (medlineplus.gov)
Responses to cisplatin1
- In this paper, we primarily focused on recent studies on cellular responses to cisplatin-induced DNA damage although we briefly discussed steps leading to cisplatin-induced DNA damage. (hindawi.com)
Docetaxel and cisplatin3
- Docetaxel and cisplatin is used to treat non-small cell lung cancer. (macmillan.org.uk)
- Each cycle of docetaxel and cisplatin takes 21 days (3 weeks). (macmillan.org.uk)
- On the first day, you will have docetaxel and cisplatin. (macmillan.org.uk)
Gemcitabine and Cisplatin1
- This study will also help in finding out the effect on tumor of the combination of enzalutamide, gemcitabine and cisplatin. (clinicaltrials.gov)
Platinum-based chemotherapeutic1
- Cisplatin and other platinum-based chemotherapeutic agents are routinely used in treating numerous tumor types with approximately 500,000 patients including 2,000 children treated each year in the United States. (cnbc.com)
Chemotherapeutic2
Tumor growth4
- Furthermore, combined treatment with a hsp90 inhibitor and the MAST1 inhibitor lestaurtinib further abrogated MAST1 activity and consequently enhanced cisplatin-induced tumor growth arrest in a patient-derived xenograft model. (jci.org)
- Through a metabolism-related kinome RNAi screen, we identified inositol-trisphosphate 3-kinase B (ITPKB) as a critical enzyme that contributes to cisplatin-resistant tumor growth. (jci.org)
- We demonstrated that inositol 1,3,4,5-tetrakisphosphate (IP4), the product of ITPKB, plays a critical role in redox homeostasis upon cisplatin exposure by reducing cisplatin-induced ROS through inhibition of a ROS-generating enzyme, NADPH oxidase 4 (NOX4), which promotes cisplatin-resistant tumor growth. (jci.org)
- Combined AZD8055 and cisplatin treatment resulted in effective mTORC1/2 inhibition, increased caspase-3 activity, and enhanced tumor growth inhibition. (rug.nl)